Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/11/01/2770774/0/en/Spexis-Announces-Changes-to-the-Executive-Committee.html
https://www.globenewswire.com//news-release/2023/10/06/2755891/0/en/Spexis-to-host-business-update-conference-call-on-October-9-2023.html
https://www.globenewswire.com//news-release/2023/09/29/2751738/0/en/Spexis-provides-business-update-and-announces-financial-results-for-the-first-half-of-2023.html
https://www.globenewswire.com//news-release/2023/09/28/2750884/0/en/Spexis-announces-the-appointment-of-Gon%C3%A7alo-Bernardes-Ph-D-as-acting-Head-of-Chemical-Biology.html
https://www.globenewswire.com/news-release/2023/08/15/2725169/0/en/Spexis-announces-USD-2-5-million-capital-commitment-to-support-the-upcoming-Phase-3-ColiFin-studies.html
https://www.globenewswire.com/news-release/2023/06/30/2697522/0/en/Spexis-announces-engagement-with-Maxim-Group-LLC-as-M-A-advisor-to-support-evaluation-of-strategic-transactions.html
https://www.globenewswire.com/news-release/2023/06/07/2683440/0/en/Spexis-announces-the-publication-of-promising-results-for-a-novel-class-of-macrocyclic-peptidomimetic-antibiotics-in-Science-Advances-demonstrating-potent-in-vitro-and-in-vivo-anti.html
https://www.globenewswire.com/news-release/2023/04/18/2648611/0/en/Spexis-announces-closing-of-capital-commitment-of-USD-4-5-million-from-SPRIM-Global-Investments-SGI-to-enable-initiation-of-ColiFin-Phase-3-study.html
https://www.globenewswire.com/news-release/2023/02/08/2603645/0/en/Spexis-and-SPRIM-Global-Investments-SGI-Announce-Plans-for-Clinical-Trial-Partnership-to-Fund-up-to-Half-of-the-Projected-Phase-3-Clinical-Development-Costs-of-ColiFin.html
https://www.globenewswire.com/news-release/2023/01/09/2584785/0/en/Spexis-reports-solid-safety-and-pharmacokinetics-results-from-first-in-human-study-with-inhaled-murepavadin-a-novel-macrocycle-compound.html